Semax Nasal Spray: Measurement, Stability & Research Data

Updated September 2026: this revision replaces the earlier step-by-step delivery walkthrough with laboratory-framed measurement arithmetic, an expanded diluent and storage comparison built only from citable sources, documented degradation signs, and an honest inventory of the Semax questions that published data still does not answer.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, constructed from the ACTH(4-7) fragment of adrenocorticotropic hormone extended with a C-terminal Pro-Gly-Pro tripeptide. The Pro-Gly-Pro extension was designed to slow enzymatic cleavage relative to the parent ACTH fragment, and the resulting molecule has been studied predominantly in Russian and Eastern European laboratories in models of cerebral ischaemia, experimental parkinsonism, chronic stress and, more recently, Alzheimer's-type pathology. Semax is supplied by Real Peptides strictly as a research chemical for in vitro and laboratory investigation. It is not approved by the U.S. Food and Drug Administration for any indication, it is not a supplement, and nothing on this page describes use in humans or animals outside a controlled research context.

The material below is organised around three practical problems that appear in laboratory purchasing and bench documentation: how published work has actually parameterised intranasal Semax investigations, how milligram, microgram and millilitre quantities convert into the volumes a metered spray device or a graduated syringe can measure, and what stability and degradation documentation exists — or, critically, does not exist — for peptide solutions of this type. Where a claim rests on a published study, the citation appears in the same sentence. Where no citable study exists, the text says so plainly rather than inventing a number.

What this page documents:

• The frequency and course-length parameters described in published Semax animal studies, and why those are experimental design details rather than instructions.
• Step-by-step laboratory reconstitution practice for lyophilised heptapeptides, including solvent selection, swirl-versus-shake handling, and labelling conventions.
• Worked mg-to-mcg-per-actuation arithmetic using neutral illustrative quantities, plus U-100 syringe unit conversion for measuring small solvent volumes.
• A condition-by-condition comparison table covering bacteriostatic water, sterile water, saline, formulated nasal vehicles, and refrigerated, ambient and frozen storage, with the evidence status for each row stated explicitly.
• Visual and analytical degradation signs — turbidity, particulates, discoloration, cake collapse, odour change, pH drift and assay-confirmed potency loss — as they are described in peptide handling documentation.
• An expanded account of the specific sub-questions that published literature on Semax leaves unanswered.

How Often Is Semax Nasal Spray Used in Published Research?

Published Semax investigations most commonly describe repeated daily intranasal delivery over a defined experimental course of several days to a few weeks, rather than a single exposure or indefinite continuous use. That is the honest summary of the design patterns visible across the indexed literature, and it is an experimental parameter reported by investigators working in rodent models — not a recommendation, and not a figure that transfers to any other context. Study designs vary because the endpoints vary: an acute cerebral ischaemia model measures gene transcription within hours to days of insult, while a neurodegeneration model measures behavioural change over weeks.

Work on neurotrophin transcription reported that Semax and its Pro-Gly-Pro fragment activated transcription of neurotrophins and their receptor genes after cerebral ischaemia in rats (PMID 19633950), an endpoint that is measured in the hours and days following the ischaemic event and therefore drives a short, tightly spaced delivery course. A later transcriptome-level analysis examined protective properties of ACTH(4-7)PGP following cerebral ischaemia-reperfusion in rats and characterised changes across large panels of transcripts (PMID 32580520), again within an acute post-insult window. Behavioural and histological endpoints extend the window: neuroprotective and antiamnesic effects were assessed during experimental ischaemic infarction of the cerebral cortex (PMID 17603664), and effects on the behaviour of rats with 6-OHDA-induced parkinsonism-like pathology were evaluated over a longer observation period (PMID 28702721).

Chronic-exposure designs appear as well. Investigators examined the morphofunctional state of hepatocytes under chronic emotional and painful stress with Semax exposure (PMID 28577097), and a separate group evaluated anticoagulation and antiplatelet effects under both acute and chronic immobilisation stress (PMID 21113455) — designs in which repeated delivery across a multi-day stress paradigm is intrinsic to the model. A 2025 report evaluated Semax and a derivative for correcting pathological impairments in an animal model of Alzheimer's disease (PMID 41479572), and network-level analysis has been applied to compare Selank and Semax effects using a functional connectomic approach (PMID 32342318).

Two caveats matter for anyone reading frequency figures out of these papers. First, rodent nasal anatomy, mucociliary clearance rate and olfactory epithelium surface fraction differ substantially from other species, so an exposure interval optimised for a rat model is not a transferable parameter. Second, the indexed literature reports what was done, not what is optimal; almost none of these studies included a systematic frequency-ranging arm. Laboratories designing new work generally derive their own exposure interval from pilot data and record it in the study protocol document rather than importing it from a prior paper.

How Is Semax Nasal Spray Mixed for Laboratory Use?

Lyophilised Semax is mixed by introducing a measured volume of an appropriate solvent slowly down the inner wall of the vial, allowing the cake to dissolve without agitation, then swirling gently and labelling the vial with concentration, solvent, date and operator. That sequence — measure, introduce slowly, dissolve passively, swirl, label — is the standard handling practice for small lyophilised peptides across research laboratories, and each step exists to prevent a specific failure mode.

Why solvent is introduced slowly and vials are swirled rather than shaken

Directing the solvent stream straight into the lyophilised cake at speed generates shear and foam. Foaming drives peptide to the air-liquid interface, which is the classic site of surface-induced unfolding and aggregation for polypeptides, and it also traps material in bubbles that never redissolve fully, producing a solution whose actual concentration is lower than the arithmetic predicts. Running the stream down the wall lets the cake wet from underneath. Vigorous shaking compounds the same problem. Gentle swirling, or simply leaving the vial upright at refrigerated temperature until the cake clears, is the documented alternative. A fully reconstituted heptapeptide solution at typical research concentrations should be clear and colourless with no visible particulates; anything else is a reason to quarantine the vial and check the certificate of analysis at /coas against the lot number.

Solvent selection and what "reconstitution" means in different literatures

Research laboratories generally reconstitute lyophilised peptides with bacteriostatic water (water containing benzyl alcohol as a preservative), sterile water for injection, or a buffered vehicle appropriate to the downstream assay. Preserved water is chosen when a solution will be entered repeatedly over days; unpreserved water or buffer is chosen when preservative interference with an assay is a concern. Notably, there is no head-to-head published comparison of these solvents for Semax specifically in the citable literature. The closest methodologically relevant head-to-head diluent study in the cited set examined reconstitution of injectable poly-d,l-lactic acid with different diluents and an accelerating method (PMID 33154871) — a polymer suspension, not a peptide, which makes it an illustration of how diluent comparisons are designed rather than a source of Semax figures.

It is worth noting that the word "reconstitution" carries several unrelated meanings in indexed biomedical literature, which frequently frustrates literature searches. In natural-product chemistry it describes rebuilding a biosynthetic pathway in vitro, as in heterologous and in vitro reconstitution of the lasso peptide fuscanodin (PMID 30532970) and enzymatic reconstitution of the lasso peptide fusilassin (PMID 30589265). In immunology it describes restoration of a cellular compartment, as in transient hepatic reconstitution of trophic factors and aged immunity (PMID 41407851). None of these describe vial reconstitution of a lyophilised research peptide, and treating them as if they did is a common citation error.

The mixing sequence laboratories document

1. Equilibrate. The vial is allowed to reach ambient temperature before the stopper is pierced, which reduces condensation inside the vial and pressure differentials that cause solvent to spit back through the septum.
2. Sanitise closures. Both the peptide vial septum and the solvent vial septum are wiped with isopropyl alcohol and allowed to dry.
3. Draw a measured solvent volume. The volume is recorded, not estimated, because every downstream concentration figure derives from it.
4. Introduce slowly down the wall. Needle bevel against the glass, slow plunger travel, no direct jet onto the cake.
5. Dissolve passively, then swirl. No shaking, no vortexing unless the assay method specifies it.
6. Inspect against light and dark backgrounds. Clarity, colour and absence of particulates are checked and recorded.
7. Transfer to the spray device, if applicable. Nasal actuator assemblies have a measurable dead volume and require priming actuations before delivered volume stabilises.
8. Label completely. Peptide identity, lot, concentration in mg/mL, solvent, reconstitution date, storage location and operator initials.

Semax Nasal Spray Quantities in Study Reports: mcg, mg and mL Explained

Searches for Semax nasal spray quantity figures generally return numbers copied between vendor pages without a traceable source, and the citable literature does not supply a validated figure for any non-research context. What the literature does supply is a set of experimental parameters expressed in micrograms per unit body mass of laboratory animals, chosen by investigators for the specific model being studied — parameters that are meaningless outside that model and that this page therefore does not reproduce as a number. The useful and transferable skill is unit arithmetic: understanding how a stated vial content in milligrams becomes a concentration in mg/mL, and how that concentration becomes a microgram quantity per metered actuation. That arithmetic is the subject of the next section, and it is presented with neutral illustrative figures chosen to make the mathematics legible rather than to describe any quantity intended for use.

Three unit conventions cause most of the confusion in peptide records. First, vial contents are stated in milligrams of peptide, not milligrams of total lyophilised mass; salt counter-ions, residual buffer and bulking agents all contribute mass that is not peptide, which is why the certificate of analysis reports peptide content separately from purity. Second, 1 mg equals 1,000 mcg, so a decimal-point error converts a microgram-scale figure into a milligram-scale one — a thousand-fold error that is the single most common arithmetic failure in peptide records. Third, concentration is a ratio, not a quantity: the same 10 mg of peptide produces very different mg/mL figures depending on solvent volume, and any record listing a concentration without the solvent volume it derives from is incomplete.

Concentration Math: Converting mg, mcg and mL for Nasal Spray Solutions

The governing relationship is simple: concentration (mg/mL) equals peptide mass (mg) divided by solvent volume (mL). Every other figure in a peptide record is derived from that ratio. The examples below use round, neutral numbers purely to demonstrate the arithmetic.

Worked example one: vial content to concentration

A vial whose certificate states 10 mg of peptide content, reconstituted with 5 mL of solvent, yields 10 ÷ 5 = 2 mg/mL. Expressed in micrograms, that is 2,000 mcg per millilitre. Reconstituting the same 10 mg vial with 10 mL yields 1 mg/mL, or 1,000 mcg/mL. Reconstituting it with 2 mL yields 5 mg/mL, or 5,000 mcg/mL. The peptide mass never changes; only the ratio does. This is why laboratories record solvent volume as a primary data point and treat any vial found without that record as unquantified.

Worked example two: concentration to micrograms per actuation

Metered nasal actuators are specified by delivered volume per actuation, commonly in the range of 0.05 mL to 0.14 mL depending on the pump. If a device is specified at 0.1 mL per actuation and the solution is 2 mg/mL, then each actuation delivers 0.1 mL × 2,000 mcg/mL = 200 mcg of peptide in the sprayed volume. At 1 mg/mL the same device delivers 100 mcg per actuation; at 5 mg/mL it delivers 500 mcg. Two independent variables — pump specification and solution concentration — therefore determine the microgram figure, and a record that states only one of them cannot be reconstructed later.

Worked example three: total actuations available per vial

Total sprayable actuations equal usable solution volume divided by delivered volume per actuation, minus priming losses and dead volume. A 5 mL fill in a device specified at 0.1 mL per actuation gives a theoretical 50 actuations, but priming consumes several actuations at the start, and the pump dip tube cannot draw the final residual volume in the reservoir. Device-specific dead volume is typically a fraction of a millilitre and is the reason theoretical actuation counts overstate practical ones. Laboratories that need accurate accounting weigh the device before and after a defined number of actuations to establish the real delivered mass per actuation rather than relying on the nominal specification.

U-100 insulin syringe units when measuring small volumes

Small solvent and aliquot volumes are frequently measured with U-100 insulin syringes, which are graduated in insulin units rather than millilitres. The conversion is fixed: a U-100 syringe carries 100 units per 1 mL, so 1 unit equals 0.01 mL, 10 units equal 0.1 mL, 25 units equal 0.25 mL, 50 units equal 0.5 mL and 100 units equal the full millilitre. Combining that with a concentration figure gives micrograms per unit: at 2 mg/mL, each 0.01 mL unit contains 20 mcg; at 1 mg/mL, each unit contains 10 mcg; at 5 mg/mL, each unit contains 50 mcg. The unit marking itself carries no mass information — it is a volume graduation only — which is why concentration must always be recorded alongside it. Syringe graduation error is proportionally largest at the low end of the barrel, so laboratories measuring very small volumes typically select the smallest-capacity syringe that will hold the target volume rather than measuring a few units in a 1 mL barrel.

Reading a certificate of analysis for vial contents

A certificate of analysis is the document that makes the arithmetic above meaningful, because it states what is actually in the vial. The fields that matter for quantification are peptide identity and sequence, net peptide content, chromatographic purity (usually by RP-HPLC, with the method and gradient noted), identity confirmation by mass spectrometry with observed versus theoretical monoisotopic mass, water content by Karl Fischer titration, residual solvent and counter-ion content, and where applicable endotoxin and bioburden results. Purity and net peptide content are not the same figure: a lot can be 99% chromatographically pure while containing meaningfully less than the nominal mass in peptide because of salt and water. Real Peptides publishes an independent certificate for every lot at /coas, and the standard laboratory practice is to match the lot number printed on the vial against the certificate before the first reconstitution, then file the certificate with the reconstitution record.

Semax After Reconstitution: What Stability Documentation Reports

Stability documentation for research peptides distinguishes sharply between the lyophilised solid and the reconstituted solution, and the difference is chemical rather than procedural. In the lyophilised state, water activity is low, molecular mobility is restricted and the dominant degradation pathways are slow; residual moisture content, measured by Karl Fischer titration and reported on the certificate, is the variable that most strongly predicts solid-state shelf life. Once solvent is introduced, hydrolytic pathways become accessible, and the solution enters what pharmaceutical documentation calls the in-use period — the window after first entry during which the product remains within specification under stated storage conditions.

For Semax specifically, the citable literature in this set does not contain a published in-use stability study reporting assay-confirmed potency at defined timepoints in a defined diluent. That absence is stated plainly here because filling it with borrowed numbers would be fabrication. What can be documented is the general framework laboratories apply: lyophilised material stored frozen and protected from light and moisture, reconstituted solution stored refrigerated in the range manufacturers typically specify for aqueous peptide solutions, minimal time at ambient temperature, avoidance of repeated freezing and thawing of solutions, and quarantine of any container showing a change in appearance.

Several structural features of Semax are relevant to which degradation pathways are chemically plausible, independent of any measured data. The sequence begins with methionine, and methionine sulfoxide formation is one of the best-characterised oxidative modifications in peptide chemistry, producing a mass increase of 16 Da detectable by LC-MS and typically an additional, earlier-eluting peak in reversed-phase chromatography. The sequence also contains glutamic acid and histidine; acidic residues participate in pH-dependent hydrolysis, and histidine is a recognised site of metal-catalysed oxidation. The three proline residues and the Pro-Gly-Pro motif contribute conformational rigidity and were the design rationale for improved enzymatic resistance relative to the parent ACTH fragment. None of this constitutes a measured stability figure; it identifies which analytical signals a stability-indicating method would be designed to detect.

Formulation literature demonstrates that the vehicle itself can dominate intranasal peptide behaviour. Brain-targeting polymeric micelles were developed as an intranasal carrier system for rapamycin in an Alzheimer's disease model (PMID 40780467), illustrating that carrier chemistry, not just the active molecule, determines what reaches the target compartment. A simple aqueous solution of a peptide in water is a different physical system from a formulated nasal product with viscosity modifiers, tonicity agents, buffer and preservative, and stability figures generated for one do not transfer to the other.

Diluents and Storage Conditions Compared: What the Cited Data Reports

The table below lists each diluent and storage condition discussed on this page alongside what the cited literature actually supports for that row. The evidence column is deliberately blunt: most rows have no Semax-specific published in-use stability data in the citable set, and saying so is more useful to a laboratory buyer than a confident number with no provenance.

Read as a whole, the table makes one point that vendor pages rarely concede: the confident-sounding stability figures circulating for intranasal Semax do not trace back to published, assay-confirmed studies of this peptide in these diluents. Laboratories that need those numbers for their own work generate them internally with a stability-indicating HPLC method, or they design experiments so that solutions are prepared fresh and the question does not arise.

Visual and Analytical Signs of Degradation in Peptide Solutions

Appearance checks are the first screen, and they are performed against both a dark and a light background under good illumination, because different defects are visible against different backgrounds. Particulates and fibres show against dark; haze and colour shifts show against white.

Signs visible without instrumentation

• Turbidity or haze. A solution that was clear at reconstitution and later reads cloudy indicates that material has come out of solution or that subvisible aggregates have grown into the visible range. Haze that clears on gentle warming may reflect solubility limits; haze that persists does not.
• Visible precipitate or flocculant material. Discrete particles, flakes or a settled layer at the vial base are a quarantine finding. Wispy, thread-like material can indicate fibrillar aggregation.
• Discoloration. Development of a yellow, amber or brown tint in a solution that was colourless is a classic non-specific degradation signal, associated in peptide chemistry with oxidation and Maillard-type reactions when reducing sugars are present as excipients.
• Cake defects in the lyophilised solid. Collapse, shrinkage, melt-back, browning or a cake that has slumped from its original cylindrical form suggests a thermal excursion or moisture ingress before reconstitution ever occurs.
• Slow or incomplete dissolution. A cake that previously dissolved in seconds and now requires prolonged swirling has usually changed physically, often through moisture uptake.
• Odour change. A sharp or sulfurous note, or a change in the characteristic aromatic note of benzyl-alcohol-preserved water, is a handling observation that laboratories record; it is never a stand-alone specification but it prompts closer inspection.
• Closure integrity findings. Coring of the septum, a lifted or loose crimp, vacuum loss on first entry, or moisture under the seal all bear on whether the contents can be considered protected.

Signs requiring analytical confirmation

• Chromatographic purity loss. A stability-indicating reversed-phase HPLC method resolves the parent peak from degradants; loss of parent peak area with corresponding growth of earlier- or later-eluting peaks is the definitive potency finding. Visual inspection cannot detect this.
• Mass shifts by LC-MS. A +16 Da species is consistent with oxidation, most plausibly at the N-terminal methionine of Semax; +1 Da shifts are consistent with deamidation; fragment masses corresponding to sequence truncation indicate hydrolytic cleavage.
• pH drift. Measurable movement of solution pH over the in-use period can accompany hydrolysis or absorption of atmospheric carbon dioxide and is recorded where the assay is pH sensitive.
• Subvisible particle counts. Light obscuration or flow imaging detects aggregate populations below the visual threshold, which matters because visible haze is a late-stage signal.
• Moisture ingress in the solid. Karl Fischer titration on retained solid quantifies water uptake that a visual cake inspection may miss.

Two principles follow from the list. First, appearance is a one-way test: an abnormal appearance is strong evidence of a problem, but a normal appearance is not evidence of retained potency, because the earliest and most common degradation events are chromatographically visible long before they are optically visible. Second, appearance findings are interpreted against the baseline recorded at reconstitution; a laboratory that never documented what the solution looked like on day zero has nothing to compare against.

What Published Semax Studies Actually Measured

Understanding what the primary literature measured — and in which species — prevents the most common misreading of Semax claims. The body of work is substantially preclinical.

Cerebral ischaemia and transcription. One study reported that Semax and Pro-Gly-Pro activated transcription of neurotrophins and their receptor genes after cerebral ischaemia in rats (PMID 19633950), placing neurotrophic gene expression rather than direct receptor agonism at the centre of the proposed mechanism. Transcriptome-wide analysis extended that picture, characterising protective properties of ACTH(4-7)PGP at the transcriptome level following cerebral ischaemia-reperfusion in rats (PMID 32580520), which allows differential expression across broad gene sets rather than a handful of targeted transcripts.

Infarct models and behaviour. Neuroprotective and antiamnesic effects were evaluated during experimental ischaemic infarction of the cerebral cortex (PMID 17603664), combining histological and behavioural readouts in the same rodent model.

Parkinsonism-like models. Semax and Selank were compared for effects on the behaviour of rats with 6-OHDA-induced parkinsonism-like pathology (PMID 28702721), one of the few reports placing the two peptides side by side in a single model.

Alzheimer's-type models. A 2025 report examined the potential of Semax and a derivative for correcting pathological impairments in an animal model of Alzheimer's disease (PMID 41479572), extending the peptide's investigation beyond acute ischaemia into chronic neurodegeneration models.

Peripheral and systemic endpoints. Not all Semax work is neurological. Investigators examined the morphofunctional state of hepatocytes under chronic emotional and painful stress (PMID 28577097), and a separate study reported anticoagulation and antiplatelet effects under acute and chronic immobilisation stress conditions (PMID 21113455) — a haemostatic signal that is frequently omitted from summaries focused only on cognition-related endpoints.

Network-level analysis. A functional connectomic approach has been applied to studying Selank and Semax effects (PMID 32342318), representing a methodological shift from single-target pharmacology toward network-level characterisation.

Intranasal Peptide Delivery in the Broader Literature

Semax is studied intranasally because the nasal cavity offers routes to the central nervous system along olfactory and trigeminal pathways and because peptides are poorly suited to oral delivery. The broader intranasal peptide literature — which involves molecules other than Semax — establishes that the route is viable and actively developed, while also showing how much depends on formulation and study design.

Controlled clinical evaluation of intranasal peptides exists: intranasal oxytocin was assessed for obesity in a trial reported in NEJM Evidence (PMID 38815173), demonstrating that the route can be studied under rigorous randomised conditions. Mucosal immunology work shows the nasal compartment is biologically active in its own right: an intranasal booster was reported to drive class switching and homing of memory B cells for a mucosal IgA response (PMID 41433108).

Antiviral peptide work illustrates delivery feasibility for peptide actives specifically. A pan-coronavirus peptide inhibitor was reported to prevent SARS-CoV-2 infection in mice via intranasal delivery (PMID 37574525), and a broad-spectrum macrocyclic peptide inhibitor administered intranasally was reported to protect against SARS-CoV-2 Omicron variants (PMID 41587975). Vaccine and nanomedicine work extends the range of intranasal peptide constructs: intranasal delivery of HPV therapeutic vaccines was evaluated for enhanced mucosal immunisation and anti-tumour immunity (PMID 40794451), and sequential intranasal and intravenous survivin peptide-CpG nanovaccines were reported to elicit immunity toward glioblastoma (PMID 40489066).

For CNS-directed small peptides, the closest methodological neighbour in this citable set is work reporting that an intranasal GHK peptide enhanced resilience to cognitive decline in aging mice (PMID 38014118), which is a preprint and therefore had not completed peer review at the time of indexing — a status worth noting whenever it is cited. Carrier engineering for the same route is represented by brain-targeting polymeric micelles developed for intranasal rapamycin (PMID 40780467).

Handling Variables That Change Results in Nasal Spray Work

Once concentration is fixed, most of the remaining variability in intranasal research comes from the device and the handling, not the molecule. Laboratories that report reproducible results typically control the following.

Device priming and delivered volume

Metered pumps do not deliver their nominal volume until the chamber and dip tube are filled. Priming actuations into waste are counted and recorded, and the number required is device specific. Pumps that sit unused for extended periods can lose prime and require re-priming. Where quantification matters, gravimetric verification — weighing the assembly before and after a counted series of actuations and dividing by the count — gives the true mean delivered mass per actuation, which frequently differs from the specification sheet.

Temperature equilibration and viscosity

Solutions drawn directly from refrigerated storage are more viscous than equilibrated ones, and viscosity affects both pump output volume and spray plume geometry. Allowing the device to reach ambient temperature before a counted actuation series removes one source of between-session variation.

Dead volume and end-of-container behaviour

The final residual volume in a reservoir cannot be drawn by the dip tube, and actuations attempted at that point deliver inconsistent or partial volumes. Records that assume a full theoretical actuation count from a given fill volume will overstate delivered material toward the end of the container.

Container material and closure

Peptides adsorb to surfaces, and adsorptive loss is proportionally greatest for dilute solutions in high-surface-area containers. Container material, whether type I glass or a polymer, is recorded because it bears on both adsorption and potential leachables. No cited study in this set quantifies adsorptive loss for Semax specifically, which is another reason laboratories verify concentration analytically rather than assuming it.

Documentation practice

A usable record for a reconstituted nasal preparation contains, at minimum: peptide identity and lot, certificate reference, solvent identity and volume, calculated concentration in mg/mL, device identity and nominal delivered volume, priming actuation count, date and time of reconstitution, storage location and temperature, and appearance at reconstitution and at each subsequent entry. Records built this way can be reconstructed years later; records that list only a microgram figure cannot.

Scenarios Laboratories Record in Handling Logs

Certain events recur in intranasal research work, and the useful response in each case is documentation rather than improvisation.

A blocked or inconsistent actuator. Crystallised solute at the orifice, an air lock in the dip tube, or a partially seated pump can all reduce or eliminate output. Laboratories record the event, verify output gravimetrically after clearing, and note whether any actuations of uncertain volume occurred during the affected session, because those sessions cannot be treated as quantified.

Material lost to drainage rather than mucosal contact. In model work, a fraction of any nasally delivered volume can drain posteriorly and be swallowed, where gastrointestinal proteolysis applies. This is a recognised source of between-session variability in intranasal studies generally and is a reason investigators standardise head or body positioning within a model and record any deviation.

A missed session in a repeated-exposure design. The relevant action is a protocol deviation entry describing what was missed and when, so that the analysis can account for it. Substituting a doubled subsequent exposure alters the exposure profile and invalidates comparison with the planned design.

Local mucosal irritation observed in a model. Irritation findings are recorded as observations with the solution's composition, tonicity, pH and preservative content noted alongside, because vehicle properties rather than the peptide are frequently implicated. Where irritation is an endpoint of interest, formulation variables are controlled deliberately.

A temperature excursion. Storage temperature deviations are logged with duration and peak temperature. Because no cited study in this set defines an excursion tolerance for Semax solutions, affected material is either verified analytically or treated as compromised — the two defensible options.

What the Literature Does Not Cover

This section is deliberately specific, because the gap between what is asserted about Semax online and what is published is wide, and naming the unanswered questions is more useful than papering over them.

• Hour-by-hour in-use stability of Semax at a defined concentration. No cited study reports assayed potency for a Semax solution at, for example, 1 mg/mL or 2 mg/mL sampled at 0, 24, 48, 72 hours and beyond. The commonly quoted in-use windows for reconstituted peptide solutions are general handling conventions, not Semax measurements.
• Head-to-head diluent comparisons for Semax. There is no published side-by-side comparison of bacteriostatic water, sterile water, saline and buffered vehicles for this peptide. The nearest methodological analogue in the cited set compares diluents for a non-peptide injectable poly-d,l-lactic acid preparation (PMID 33154871), which cannot substitute for peptide data.
• Freeze-thaw tolerance expressed as a cycle count. No cited study establishes how many freezing and thawing transitions a Semax solution withstands before measurable purity loss. Single-use aliquoting is a precaution, not a published threshold.
• Photostability. No cited study reports Semax solution or solid exposed to defined light conditions under ICH-style photostability testing with chromatographic follow-up.
• Container and closure interactions. Adsorptive loss to glass versus polymer, leachables from nasal pump components, and silicone oil interactions are unquantified for this peptide in the cited set.
• Delivered-volume validation for nasal devices holding peptide solutions. No cited study reports actuation-level delivered mass reproducibility for Semax solutions in any specific pump.
• Route-comparative bioavailability figures. The frequently repeated percentage figures comparing intranasal with other routes for Semax do not trace to a study in this citable set. The broader intranasal literature demonstrates that the route works for peptide actives (PMID 37574525, PMID 41587975) without supplying a Semax-specific bioavailability number.
• Species translation. The Semax evidence base cited here is preclinical and rodent-dominated (PMID 17603664, PMID 28702721, PMID 41479572); no study in this set establishes translation of those endpoints to other species.
• Long-term exposure characterisation. Chronic-stress designs report specific peripheral endpoints (PMID 28577097, PMID 21113455) but do not constitute long-term safety characterisation.
• Search-term contamination. A literature search for "dose accuracy" returns predominantly radiotherapy physics — for example, dose calculation accuracy on iterative CBCT for head and neck radiotherapy (PMID 34102546), deep learning applied to radiotherapy dose calculation (PMID 32559018), small-field photon beam calculation accuracy (PMID 36567632) and algorithm accuracy with dental amalgam (PMID 39141184) — none of which relate to peptide measurement. Similarly, "reconstitution" retrieves enzymatic pathway reconstitution (PMID 30532970, PMID 30589265) and immune reconstitution (PMID 41407851). The apparent volume of results conceals a genuine absence of vial-level peptide stability studies.

The practical consequence for a laboratory buyer is straightforward: the parameters that can be verified for a given lot — identity, purity, net peptide content, moisture, endotoxin — come from the certificate of analysis for that lot, published at /coas. The parameters that cannot be verified from published Semax literature, particularly in-use stability curves and diluent rankings, have to be generated internally or designed around. Distinguishing the two categories is the difference between a documented experiment and an assumed one.

References

• PMID 32342318 — Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences, 2020.
• PMID 41479572 — The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease. Acta Naturae, 2025.
• PMID 28577097 — Influence of ACTG(4-7)-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress. Bulletin of Experimental Biology and Medicine, 2017.
• PMID 19633950 — Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology, 2010.
• PMID 21113455 — Anticoagulation and antiplatelet effects of semax under conditions of acute and chronic immobilization stress. Bulletin of Experimental Biology and Medicine, 2010.
• PMID 17603664 — Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex. Bulletin of Experimental Biology and Medicine, 2006.
• PMID 28702721 — Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Doklady Biological Sciences, 2017.
• PMID 32580520 — Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes, 2020.
• PMID 41407851 — Transient hepatic reconstitution of trophic factors enhances aged immunity. Nature, 2026.
• PMID 34102546 — Accuracy of dose calculation on iterative CBCT for head and neck radiotherapy. Physica Medica, 2021.
• PMID 30532970 — Heterologous and in Vitro Reconstitution of Fuscanodin, a Lasso Peptide from Thermobifida fusca. JACS, 2019.
• PMID 32559018 — Boosting radiotherapy dose calculation accuracy with deep learning. Journal of Applied Clinical Medical Physics, 2020.
• PMID 39141184 — The accuracy of Eclipse AXB and AAA dose algorithms with dental amalgam. Physical and Engineering Sciences in Medicine, 2024.
• PMID 30589265 — Enzymatic Reconstitution and Biosynthetic Investigation of the Lasso Peptide Fusilassin. JACS, 2019.
• PMID 33154871 — Reconstitution of Injectable Poly-d,l-lactic Acid: Efficacy of Different Diluents and a New Accelerating Method. PRS Global Open, 2020.
• PMID 36567632 — Evaluating Mobius3D Dose Calculation Accuracy for Small-Field Flattening-Filter-Free Photon Beams. Technology in Cancer Research & Treatment, 2022.
• PMID 41433108 — Intranasal booster drives class switching and homing of memory B cells for mucosal IgA response. JCI Insight, 2026.
• PMID 38815173 — Intranasal Oxytocin for Obesity. NEJM Evidence, 2024.
• PMID 41587975 — Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants. Nature Communications, 2026.
• PMID 40794451 — Intranasal Delivery of HPV Therapeutic Vaccines for Enhanced Mucosal Immunization and Anti-Tumor Immunity. ACS Nano, 2025.
• PMID 40489066 — Intranasal and Intravenous Sequential Administration of Survivin Peptide-CpG Nanovaccines Elicits Potent Immunity Toward Glioblastoma. Advanced Materials, 2025.
• PMID 40780467 — Intranasal delivery of rapamycin via brain-targeting polymeric micelles for Alzheimer's disease treatment. International Journal of Pharmaceutics, 2025.
• PMID 37574525 — A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal delivery. Science China Life Sciences, 2023.
• PMID 38014118 — Intranasal GHK peptide enhances resilience to cognitive decline in aging mice. bioRxiv preprint, 2023.

Semax supplied by Real Peptides is intended for laboratory research use only. It is not a drug, food or supplement, and it is not intended for human or veterinary use. Lot-specific certificates of analysis from independent laboratories are published at /coas.